Related Articles
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma
Metastatic breast cancer with double heterozygosity for the <em>BRCA1 </em>and <em>BRCA2</em> genes responding to olaparib: A case report
Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death